Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.

Eligible patients with RAS/BRAF wild-type metastatic colorectal cancer (mCRC) received first-line modified fluorouracil, leucovorin, oxaliplatin (mFOLFOX)/panitumumab (control group, n = 217) versus modified fluorouracil, leucovorin, oxaliplatin, irinotecan (mFOLFOXIRI)/panitumumab (experimental group, n = 218).

符合条件的RAS/BRAF野生型转移性结直肠癌（mCRC）患者接受了改良的氟尿嘧啶、亚叶酸钙、奥沙利铂（mFOLFOX）/帕尼单抗（对照组，n=217）与改良的氟尿嘧啶、亚叶酸钙、奥沙利铂、伊立替康（mFOLFOXIRI）/帕尼单抗（实验组，n=218）作为一线治疗。

We present overall survival(OS) and updated outcomes in the intention-to-treatpopulation.

我们报告了意向治疗人群的总生存(OS)和更新的结果。

The median follow-up was 60.2 months (IQR, 49.3-70.0).

中位随访时间为60.2个月（四分位数间距，49.3-70.0）。

The median OS was 41.1 and 33.3 months for experimental and control groups, respectively (hazard ratio[HR], 0.79 [95% CI, 0.63 to 0.99]; P = .049).

实验组和对照组的中位总生存期分别为41.1个月和33.3个月（风险比[HR]，0.79 [95% 置信区间, 0.63至0.99]；P = .049）。

OS outcomes favored the experimental group regardless of clinical features.

无论临床特征如何，总生存期的结果均倾向于实验组。

No differences in objective response rate(primary end point; 75%/78%, odds ratio, 0.84 [95% CI, 0.54 to 1.31]; P = .442), early tumor shrinkage rate (P = .954), depth of response (P = .573), no residual tumor resection rate (P = .329), and progression-free survival(HR, 0.95 [95% CI, 0.78 to 1.16]; P = .606) were confirmed.

客观缓解率（主要终点；75%/78%，比值比，0.84 [95% 置信区间，0.54 至 1.31]；P = .442）、早期肿瘤缩小率（P = .954）、缓解深度（P = .573）、无残余肿瘤切除率（P = .329）和无进展生存期（风险比，0.95 [95% 置信区间，0.78 至 1.16]；P = .606）之间未确认差异。

Among patients alive at the time of disease progression, the median postprogression survival was 24.6 and 17.7 months for experimental and control groups, respectively (HR, 0.79 [95% CI, 0.62 to 1.01]; P = .062).

在疾病进展时仍然存活的患者中，实验组和对照组的中位进展后生存期分别为24.6个月和17.7个月（风险比，0.79 [95% 置信区间，0.62 至 1.01]；P = .062）。

Similar proportions of patients in both groups received subsequent lines of therapy (control/experimental: second line 73%/71%, third line 51%/49%, fourth line 31%/32%), as well as nonpalliative locoregional treatments (control/experimental: 16%/16%).

两组患者接受后续治疗线的比例相似（对照组/实验组：二线治疗 73%/71%，三线治疗 51%/49%，四线治疗 31%/32%），以及非姑息性局部区域治疗（对照组/实验组：16%/16%）。

Upfront mFOLFOXIRI/panitumumab significantly improves OS compared with mFOLFOX/panitumumab in patients with RAS/BRAF wild-type mCRC.

与 mFOLFOX/panitumumab 相比，一线 mFOLFOXIRI/panitumumab 显著改善了 RAS/BRAF 野生型转移性结直肠癌患者的总生存期。